
biotech discov
invent manufactur commerci medicin
treat seriou diseas
product grow risk moder extent
takeaway announc share buyback elev share
near term addit continu tri build moat around eylea
account total revenu quarter
eylea competit surfac beovu set abl defens
competit price remain key issu surround eylea continu
build moat around key product concentr risk evid
mention previous eylea account half compani revenu
compani intend launch eylea pre-fil syring help
access eas use furthermor compani conduct registr trial
wet dme high dose eylea product schedul
specif less frequent dose directli address competit novarti
dupix libtayo continu grow
dupix libtayo continu drive revenu higher market uptak increas
acknowledg product contribut higher revenu think
eylea risk could dull edg bit two product may fill hole
potenti eylea revenu loss remain encourag two product
continu grow libtayo encourag posit advanc nsclc data
object respons rate random patient libtayo vs
chemotherapi
pipelin bright spot need see data
think pipelin continu posit outlook bispecif data
continu roll includ product target bcma also look forward
next gener bispecif program incorpor costimulatori bispecif
like direct compani take drive deep oncolog
intern program extern partnership program mostli earli
take time materi
maintain hold rais pt
maintain hold rate base ad risk addit competitor
price concern relat eylea well view consensu number bit
high howev rais pt base share
buy-back buy-back alter valuat base price-to-earnings multipl note
sever headwind compani includ dupix patent ipr/
litig continu price concern eylea medicar part price initi
addit eylea competit join fray continu expect strong growth
dupix moder growth eylea may diminish competit
product obtain greater market share time
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
hold unchang target price novemb
date eylea npdr patient w/o dme completedpdufa date praluent cardiovascular risk reductioncompletedpdufa date praluent first-lin hyperlipidemia completedregulatori regulatori decis libtayo advanc cscccompletedpdufa date dupix adolesc ad completeddata data dupix pediatr non-gaap epsp multipl figur revenu build
hold unchang target price novemb
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u revenues- net product sale book praluentu ex-u ww zaltrapex-u us ww kevzarau ex-u dupixentu atop dermat uncontrol asthma estim ex-u atop dermat uncontrol asthma estim figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price novemb
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch reimburs sanofi bayer teva option non-reimburs sell gener option expens sg ex-opt collabor total oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli share dilut share outstand dilut share outstand figur balanc sheet
hold unchang target price novemb
fy pharmaceut balanc sheetasset cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens defer revenu sanofi current portion defer revenu current portion facil leas oblig current portion current liabilities- total current liabil defer revenu sanofi defer revenu facil leas oblig long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur statement
hold unchang target price novemb
fy statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict cash- flow repurchas repay note payable- proce connect facil leas obligations- payment connect facil leas obligations- net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end regeneron
